SCHEMBL233224

SCHEMBL233224

COC(=O)CCCCC(C)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.56
TSHR P16473 3/20 0.54
CYP1A2 P05177 1/20 0.48
BLM P54132 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ACE2 Q9BYF1 1/20 0.44
GABRR1 P24046 2/20 0.43
SLC1A1 P43005 1/20 0.43
PABPC1 P11940 1/20 0.40
APOBEC3A P31941 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
RECQL P46063 1/20 0.39
FAAH O00519 1/20 0.39
TBXAS1 P24557 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14360056 0.98 LTA4H (0.55) LTA4HTSHRCYP1A2BLML3MBTL1
Hydrochloric Acid SCHEMBL1228512 0.98 LTA4H (0.55) LTA4HTSHRCYP1A2BLML3MBTL1
SCHEMBL30615290 0.93 TSHR (0.60) LTA4HTSHRCYP1A2BLML3MBTL1
SCHEMBL30163316 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL29746804 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL31005827 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL30862100 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL30370163 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL30602648 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL
SCHEMBL30862098 0.91 ACE2 (0.59) LTA4HL3MBTL1LMNAACE2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2287147-B1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-15 EP disclosed
US-8350060-B2 2-amino-bicyclo[3.1.0] hexane-2, 6-dicarboxylic ester derivative Taisho Pharamceutical Co., Ltd. (JP) 2013-01-08 US disclosed
EP-2123630-B1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-20120004232-A1 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-05 US disclosed
US-8076502-B2 2-amino-bicyclo(3.1.0) hexane-2,6-dicarboxylic ester derivative TAISHO PHARMACEUTICALS CO., LTD. (JP) 2011-12-13 US disclosed
EP-2287147-A2 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed
US-20100298561-A1 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-11-25 US disclosed
EP-1637517-B1 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2010-11-10 EP disclosed
EP-2123630-A1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative Taisho Pharmaceutical Co. Ltd. (JP) 2009-11-25 EP disclosed
EP-1637517-A1 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE Taisho Pharmaceutical Co. Ltd. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298561-A1 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE GRIK4, GRIN2D, GRIN2C LTA4H 2036/4885TSHR 348/4885CYP1A2 1040/4885
US-20120004232-A1 2-AMINO-BICYCLO(3.1.0) HEXANE-2, 6-DICARBOXYLIC ESTER DERIVATIVE GRIK4, GRIN2D, GRIN2C LTA4H 2036/4885TSHR 348/4885CYP1A2 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.